United States-based Gilead Sciences has licensed The Rockefeller University's range of broadly neutralising antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.

It was reported on Friday that according to the contract, Gilead Sciences has acquired exclusive global licenses to develop and commercialise Rockefeller's complete range of HIV bNAbs. Rockefeller will receive an upfront payment and is eligible to receive cumulative milestone payments, and royalties on net sales. In addition to that, the university will retain rights to perform non-clinical and early-stage clinical research on the portfolio of HIV antibodies.

The products are investigational therapies and are not approved by any regulatory body globally; their safety and efficacy have not been established. There is no cure for HIV or AIDS.